Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carmell Co. stock logo
CTCX
Carmell
$2.44
+0.8%
$2.14
$0.17
$1.98
$51.01M0.514.32 million shs10,621 shs
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
$0.58
$0.22
$2.40
$997K0.658.25 million shs1.89 million shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.15
+6.1%
$3.19
$1.75
$9.37
$4.88M1.33799,245 shs40,375 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$0.14
-3.6%
$0.15
$0.06
$6.00
$2.84M0.43579,384 shs72,562 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carmell Co. stock logo
CTCX
Carmell
0.00%-5.79%-10.62%+1,933.33%+46.11%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
0.00%0.00%0.00%0.00%0.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+5.70%+10.53%-5.12%+67.55%+775.24%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-3.57%-2.95%-10.00%+50.00%-97.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Carmell Co. stock logo
CTCX
Carmell
N/AN/AN/AN/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
2.3892 of 5 stars
3.05.00.00.00.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carmell Co. stock logo
CTCX
Carmell
0.00
N/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
2.00
Hold$5.003,603.70% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carmell Co. stock logo
CTCX
Carmell
$32.84K1,553.28N/AN/A$1.07 per share2.28
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A$6.48 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.36N/AN/A$2.73 per share1.15
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.68M0.37N/AN/A($6.91) per share-0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carmell Co. stock logo
CTCX
Carmell
-$15.44MN/A0.00N/AN/A-217.50%-50.22%N/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-563.16%N/A-174.06%7/28/2025 (Estimated)

Latest NVIV, SNOA, CTCX, and TTOO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Carmell Co. stock logo
CTCX
Carmell
N/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carmell Co. stock logo
CTCX
Carmell
N/A
0.31
0.29
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/A
14.30
14.30
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.40
0.24

Institutional Ownership

CompanyInstitutional Ownership
Carmell Co. stock logo
CTCX
Carmell
24.22%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
13.78%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
Carmell Co. stock logo
CTCX
Carmell
29.00%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
2.45%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carmell Co. stock logo
CTCX
Carmell
1420.91 million14.84 millionNot Optionable
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
63.11 million3.03 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
18021.04 million21.04 millionOptionable

Recent News About These Companies

TTOO T2 Biosystems, Inc. - Seeking Alpha
T2 Biosystems Inc. (TTOO) After Hours Quote
T2 Biosystems initiates major layoffs, seeks asset sale
T2 Biosystems to be delisted from Nasdaq
T2 Biosystems reports preliminary Q4 revenue $2.3M
T2 Biosystems announces sale of four T2Dx Intruments to European distributor
T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped
T2 Biosystems extends multi-year supplier agreement with Vizient

New MarketBeat Followers Over Time

Media Sentiment Over Time

Carmell stock logo

Carmell NASDAQ:CTCX

$2.44 +0.02 (+0.83%)
As of 07/3/2025

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

InVivo Therapeutics stock logo

InVivo Therapeutics NASDAQ:NVIV

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.15 +0.18 (+6.06%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$3.16 +0.00 (+0.16%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

T2 Biosystems stock logo

T2 Biosystems NASDAQ:TTOO

$0.14 -0.01 (-3.57%)
As of 07/7/2025 03:59 PM Eastern

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.